HTG Raises $15.7M to Increase Adoption of Gene-expression Testing Platform | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – HTG today announced it has completed its first tranche of a Series D financing round, raising $15.7 million.

The funds will be used to increase adoption of the company's multiplex gene-expression testing platform for validation and clinical applications across different therapeutic areas, the Tucson, Ariz.-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.